IPP Bureau
Pharma overhaul: EMA hails “Once-in-a-Generation” reform
By IPP Bureau - December 16, 2025
The reform is set to modernise how medicines are developed, authorised, and made available across the EU
Sanofi flags delay in FDA review of Tolebrutinib for progressive multiple sclerosis
By IPP Bureau - December 16, 2025
Sanofi secures two breakthrough nods in China for rare blood disorders
By IPP Bureau - December 16, 2025
Qfitlia is the first antithrombin (AT)-lowering therapy approved for routine prophylaxis in hemophilia
Neuren partner Acadia bags FDA go-ahead for new DAYBUE STIX powder for Rett Syndrome
By IPP Bureau - December 16, 2025
The new powder formulation gives children and adults living with Rett syndrome greater flexibility and choice in dose volume and taste
Sobi to acquire Arthrosi Therapeutics in $950 million deal, bolstering gout pipeline
By IPP Bureau - December 16, 2025
The drug is currently being evaluated in two fully recruited global Phase 3 studies for progressive and tophaceous gout, with results expected in 2026.
Zenas BioPharma and InnoCare hit key milestone in Lupus drug trial, secures China Phase 3 nod
By IPP Bureau - December 16, 2025
The study also showed a clear dose-dependent trend, with the 75 mg QD group outperforming the 50 mg QD cohort
Alphyn Biologics bags $25 million financing to advance breakthrough skin disease therapies
By IPP Bureau - December 16, 2025
Alphyn is developing Zabalafin Hydrogel as the first therapy to simultaneously tackle the interconnected drivers of AD
Anova launches AI-powered patient matching platform to speed clinical trial enrollment
By IPP Bureau - December 16, 2025
Clinical trial enrollment has long been a bottleneck in drug development
Caplin Point Laboratories’ injectables facility completes INVIMA audit successfully
By IPP Bureau - December 15, 2025
This is also an important milestone in our product strategy for our expansion into the larger Latin American market
Indoco receives EIR from the USFDA for its API manufacturing facility at Patalganga
By IPP Bureau - December 15, 2025
Indoco received the Establishment Inspection Report from the USFDA for its API manufacturing facility
Eiko LifeSciences to acquire 51% stake in SSM Formulations
By IPP Bureau - December 15, 2025
The plant can reach an annual capacity of 300 crore tablets and 90 crore capsules
Anil Koul joins Mankind Pharma as Group Chief Scientific Officer
By IPP Bureau - December 15, 2025
More than five drug candidates from his team progressed to human trials including drugs like Rilematovir (Phase IIb), and Bedaquiline
Akums launches advanced Gabapentin ER for PHN management with RetenEx technology
By IPP Bureau - December 15, 2025
Thermo Fisher Scientific appoints Anoopa Menon as Director
By IPP Bureau - December 14, 2025
In her previous roles, Menon led significant digital transformation efforts, implementing predictive analytics, automation
Novartis appoints Vrinda Taneja as Director – People & Organisation, International India
By IPP Bureau - December 14, 2025
Her journey includes leading HR for large and diverse teams across sales, marketing, corporate functions, and R&D
